UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PR Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of
false
פרפל ביוטק בע"מ
2
380
PURPLE BIOTECH LTD
Corporation no:
520031238
12724
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
18/01/2021
www.isa.gov.il
www.tase.co.il
Reference:
2021-02-007489
Time of broadcast:
15:07
15:07
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PR Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2021 Purple Biotech LTD. PR:Purple Biotech to Present at the B. Riley Oncology Investor Conference
ea133510-pr_purplebiotechFINAL_isa.pdf
החברה תציג בכנס B. Riley
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
31/12/2020
Address:
Oppenheimer, Science Park
4
,
Rehovot
7670104
,
Israel
Tel:
03-9333121
,
03-9311321
Fax:
03-5097196
E-mail address:
ir@purple-biotech.com
Company site:
www.kitovpharma.com
Previous names of reporting entity:
KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory:
Masas Ludmer Adi
Position of Signatory in the reporting corporation:
Company Controller
Name of Employer Company:
Address:
Menachem Begin Drive
132
,
Tel Aviv
6701101
Telephone:
03-9333121
Facsimile:
03-5097196
E-mail:
adim@kitovpharma.com
1
Israel